Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 1/20 | 0.80 |
| ▸ | TTR | P02766 | 2/20 | 0.74 |
| ▸ | DPP4 | P27487 | 1/20 | 0.74 |
| ▸ | FDPS | P14324 | 1/20 | 0.71 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | APP | P05067 | 3/20 | 0.63 |
| ▸ | MAPT | P10636 | 1/20 | 0.63 |
| ▸ | CA12 | O43570 | 1/20 | 0.61 |
| ▸ | CA1 | P00915 | 1/20 | 0.61 |
| ▸ | CA2 | P00918 | 1/20 | 0.61 |
| ▸ | CA7 | P43166 | 1/20 | 0.61 |
| ▸ | CA9 | Q16790 | 1/20 | 0.61 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.61 |
| ▸ | BACE1 | P56817 | 1/20 | 0.60 |
| ▸ | TUBB4A | P04350 | 1/20 | 0.58 |
| ▸ | TUBB | P07437 | 1/20 | 0.58 |
| ▸ | TUBA3C | P0DPH7 | 1/20 | 0.58 |
| ▸ | TUBA1B | P68363 | 1/20 | 0.58 |
| ▸ | TUBA4A | P68366 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31247977 | 1.00 | MAOB (0.80) | MAOBTTRDPP4FDPSEPHX2 | |
| Ethyl Ferulate SCHEMBL21807752 | 0.89 | MAOB (1.00) | MAOBTTRDPP4FDPSEPHX2 | |
| Ethyl Ferulate SCHEMBL29392788 | 0.89 | MAOB (1.00) | MAOBTTRDPP4FDPSEPHX2 | |
| Ethyl Ferulate SCHEMBL31491261 | 0.89 | MAOB (1.00) | MAOBTTRDPP4FDPSEPHX2 | |
| Ethyl Ferulate SCHEMBL73132 | 0.89 | MAOB (1.00) | MAOBTTRDPP4FDPSEPHX2 | |
| Ethyl Ferulate SCHEMBL187331 | 0.89 | MAOB (1.00) | MAOBTTRDPP4FDPSEPHX2 | |
| Ethyl Ferulate SCHEMBL17866311 | 0.89 | MAOB (1.00) | MAOBTTRDPP4FDPSEPHX2 | |
| SCHEMBL8046251 | 0.88 | FDPS (0.84) | MAOBTTRDPP4FDPSAPP | |
| SCHEMBL8046247 | 0.88 | FDPS (0.84) | MAOBTTRDPP4FDPSAPP | |
| SCHEMBL31087309 | 0.88 | FDPS (0.84) | MAOBTTRDPP4FDPSAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8580822-B2 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2013-11-12 | — | — | US | disclosed |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2012-10-04 | — | — | US | disclosed |
| US-8247563-B2 | 5,6-dimethoxy-2-(piperidin-4-ylmethyl)-2,3-dihydro-1H-inden-1-one ; for therapy of Alzheimer's disease, myasthenia gravis, Huntingtons disease or glaucoma | REVIVA PHARMACEUTICALS, INC. (US) | 2012-08-21 | — | — | US | disclosed |
| CN-101626688-A | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS INC | 2010-01-13 | — | — | CN | disclosed |
| EP-2114166-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | Reviva Pharmaceuticals, Inc. (US) | 2009-11-11 | — | — | EP | disclosed |
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-26 | — | — | US | disclosed |
| WO-2008073452-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | REVIVA PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080153878-A1 | Compositions, synthesis, and methods of using indanone based cholinesterase inhibitors | ACHE, BCHE, CHKA | MAOB 27/4885TTR 3334/4885DPP4 417/4885 |
| US-20120252842-A1 | COMPOSITIONS, SYNTHESIS, AND METHODS OF USING INDANONE BASED CHOLINESTERASE INHIBITORS | ACHE, BCHE, CHKA | MAOB 27/4885TTR 3334/4885DPP4 417/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.